In the control group, 47% of patients with a PFS event (n = 334) received subsequent systemic therapy, 37% went on to immunotherapy, 24% had any additional chemotherapy, and 4% received platinum-doublet chemotherapy. In the group receiving the experimental regimen, 40% of patients with PFS events (n = 307) went on to receive additional systemic therapy, 8% had subsequent immunotherapy, 37% had chemotherapy, and 22% received platinum-doublet chemotherapy. In the immunotherapy and chemotherapy-alone arms, 358 and 349 patients, respectively, received active treatment. Stratification was performed by PD-L1 expression level (<1% or ≥1%), sex, and histology (squamous or nonsquamous).
#Checkmate 9la asco 2021 trial
The primary end point of the trial was overall survival (OS), with secondary and exploratory outcome measures of progression-free survival (PFS), objective response rate (ORR), efficacy by PD-L1 expression level, and safety. Patients in the chemotherapy arm with nonsquamous histology had the option to continue with pemetrexed maintenance. Patients were randomized in a 1:1 fashion to either 2 cycles of chemotherapy every 3 weeks with the addition of nivolumab at 360 mg every 3 weeks and ipilimumab at 1 mg/kg every 6 weeks or 3 cycles of chemotherapy. Patients included on the trial were those with stage IV NSCLC without prior systemic therapy for their disease and an ECOG performance status of 0 or 1 (n = 719). These data indicate a benefit of the combination across key patient subgroups characterized by PD-L1 expression, histology, and the presence of central nervous system metastases. 1ĭata from this trial, which initially led to the approval of the combination in patients with either frontline metastatic or recurrent NSCLC who did not harbor EGFR or ALK tumor mutations,2 were presented by Martin Reck, MD, PhD, of Hospital Grosshansdorf in Germany.
#Checkmate 9la asco 2021 plus
Continued efficacy is seen with nivolumab (Opdivo) and ipilimumab (Yervoy) plus 2 cycles of versus chemotherapy alone for patients with advanced non–small cell lung cancer (NSCLC), according to a 2-year follow-up analysis of the CheckMate 9LA trial (NCT03215706) presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
0 kommentar(er)
